Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 15/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.43 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
| ▸ | BLK | P51451 | 1/20 | 0.43 |
| ▸ | NEK4 | P51957 | 1/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.43 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.43 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.43 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158828 | 0.84 | CYP4F2 (0.44) | MCL1PRKCDCAMK2BCAMK2GAURKB | |
| SCHEMBL4173637 | 0.74 | MCL1 (0.71) | MCL1PRKCDCAMK2BCAMK2GAURKB | |
| SCHEMBL4171513 | 0.73 | MCL1 (0.62) | MCL1PRKCDCAMK2BCAMK2GAURKB | |
| SCHEMBL29084501 | 0.70 | CYP4F2 (0.58) | PSMD10MAPTKMT2A | |
| SCHEMBL29768576 | 0.70 | CYP4F2 (0.58) | PSMD10MAPTKMT2A | |
| SCHEMBL5068482 | 0.69 | PSMD10 (0.65) | PSMD10ALDH1A1MAPTNPSR1KMT2A | |
| SCHEMBL15622578 | 0.67 | MCL1 (0.71) | MCL1 | |
| SCHEMBL4161370 | 0.66 | PRKCD (0.84) | MCL1PRKCDCAMK2BCAMK2GAURKB | |
| SCHEMBL4168917 | 0.66 | MCL1 (0.51) | MCL1PRKCDCAMK2BCAMK2GAURKB | |
| SCHEMBL19585485 | 0.66 | PSMD10 (0.45) | MCL1PSMD10MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2134684-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9035047-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8445679-B2 | 7-substituted indole MCL-1 inhibitors | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2134684-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885PRKCD 2091/4885CAMK2B 812/4885 |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885PRKCD 2091/4885CAMK2B 812/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885PRKCD 2091/4885CAMK2B 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.